Sean Apap Mangion
YOU?
Author Swipe
View article: The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test
The ABILHAND‐23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross‐Sectional Analysis With the Nine Hole Peg Test Open
Background People with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9‐hole peg test (9HPT) is the primary clinical measu…
View article: Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial Open
National Institute for Health and Care Research Health Technology Assessment Programme, UK Multiple Sclerosis Society, and the US National Multiple Sclerosis Society.
View article: Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases
Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases Open
View article: Executive Dysfunction and Disability in <scp>SPMS</scp>: Predictive Value of the Frontal Assessment Battery in the <scp>UCLH MS</scp>‐<scp>STAT2</scp> Cohort
Executive Dysfunction and Disability in <span>SPMS</span>: Predictive Value of the Frontal Assessment Battery in the <span>UCLH MS</span>‐<span>STAT2</span> Cohort Open
Introduction Cognitive impairment is common in secondary progressive multiple sclerosis (SPMS), with executive dysfunction disproportionately so. The frontal assessment battery (FAB) is a bedside test assessing executive function. This stu…
View article: Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK Open
Introduction There remains a high unmet need for disease-modifying therapies that can impact disability progression in secondary progressive multiple sclerosis (SPMS). Following positive results of the phase 2 MS-STAT study, the MS-STAT2 p…
View article: Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population
Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population Open
The recent availability of disease modifying treatments (DMTs) for progressive multiple sclerosis (PMS) is a welcome change, yet the limitations of clinical trial design and the real-world makeup of the PMS population necessitate a balance…
View article: Comorbidity in the multiple sclerosis clinic
Comorbidity in the multiple sclerosis clinic Open
Comorbid conditions are common in people with multiple sclerosis (MS) and can lead to diagnostic delay and poorer outcomes. Neurologists have an opportunity to identify and address comorbidities within routine care, without major time or r…
View article: Validation of remote collection and quantification of blood Neurofilament light in neurological diseases
Validation of remote collection and quantification of blood Neurofilament light in neurological diseases Open
Promising blood-based biomarkers of neuropathology have emerged with potential for therapeutic development and disease monitoring. However, these tools will require specialist tertiary services for integration into clinical management. Rem…
View article: Improving the efficiency of clinical trials in multiple sclerosis
Improving the efficiency of clinical trials in multiple sclerosis Open
Background: Phase 3 clinical trials for disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) have utilized a limited number of conventional designs with a high degree of success. However, these designs limit the typ…
View article: The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
The Effect of Respiratory Viral Infections on Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Open
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolysis and thrombosis and is associated with significant morbidity and mortality. Although complement inhibitors have significantly changed the outcomes in PNH patients, brea…
View article: Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Open
This case series reports 40 patients (median age, 41 years [interquartile range (IQR) 32- 52, 22 men) with confirmed vaccine-induced immune thrombotic thrombocytopaenia after administration of their first ChAdOx1 nCov-19 (AstraZeneca) vacc…
View article: Multiplicity and Anatomical Distribution of Thrombus in Vaccine-Induced Immune Thrombotic Thrombocytopaenia Following ChAdOx1 nCov-19 Vaccination
Multiplicity and Anatomical Distribution of Thrombus in Vaccine-Induced Immune Thrombotic Thrombocytopaenia Following ChAdOx1 nCov-19 Vaccination Open
View article: COVID-19 leukoencephalopathy with subacute magnetic resonance imaging findings of vasculitis and demyelination
COVID-19 leukoencephalopathy with subacute magnetic resonance imaging findings of vasculitis and demyelination Open
View article: Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases
Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination – A report of two UK cases Open
View article: Development of forced normalisation psychosis with ethosuximide
Development of forced normalisation psychosis with ethosuximide Open
A 50-year-old man with known multidrug resistant coexistent focal and generalised epilepsy was commenced on ethosuximide, with normalisation of his electroencephalogram and cessation of absence seizures. Within 3 weeks, he developed a rapi…
View article: Continuous Positive Airway Pressure: Is it a route for infection in those with Obstructive Sleep Apnoea?
Continuous Positive Airway Pressure: Is it a route for infection in those with Obstructive Sleep Apnoea? Open
Introduction Continuous positive airway pressure (CPAP) is the standard treatment for obstructive sleep apnoea (OSA), with limited data about the prevalence of respiratory infections and microbial colonization in these patients. Objectives…
View article: Continuous positive airway pressure: Is it a route for infection in those with Obstructive Sleep Apnoea?
Continuous positive airway pressure: Is it a route for infection in those with Obstructive Sleep Apnoea? Open